Top Pharmaceutical Companies in Bengaluru (43)
At eClinical Solutions, our goal is to leverage technology to accelerate clinical research and bring life-changing therapies to patients faster. Our industry-leading elluminate® clinical data platform is used by top life sciences companies worldwide to regain control of their data and provide meaningful analytical insights.
eClinical Solutions's Top Stability & Growth Strengths
Market Expansion: Customer acquisition is continuing with more than 20 net-new biopharma and CRO customers in 2025, 20 in 2024, and additional wins in 2026, while the platform now supports 19 of the top 50 pharmaceutical companies and CROs. These signals point to expanding penetration across target life-sciences segments.
Innovation-Driven Growth: The elluminate platform is adding AI agents, automation, and risk-based quality management capabilities. These investments are positioned to attract new customers and deepen engagements with existing clients.
Investor Backing & Capital Strength: GI Partners’ majority investment in 2024, with Summit Partners retaining a minority stake, was followed by multiple C‑suite appointments in 2026. This combination signals access to capital and organizational build-out for scaling operations and technology.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
Alvotech is a global biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. Its mission is to improve patients’ lives by expanding access to affordable biologic treatments worldwide. The company operates as a fully integrated specialty biopharmaceutical business, pursuing high-quality biosimilars and building treatment options that can make important biologic therapies more accessible to patients through its research, development,...
Pharm-Olam is a global CRO that is dedicated to helping Sponsors create a healthier world through the development of life-changing treatments.
Medreich is a fully integrated Pharmaceutical Company with an established presence across the globe. We are involved in the CMO & CDMO business of pharmaceutical preparations in various dosage forms catering to diverse Therapeutic categories. Medreich has an advanced State of the Art - Research and Development Centre with proven scientific competence to develop formulations as Patent Non-infringing and Niche...
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one...
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and...
Merck KGaA, Darmstadt, Germany's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck KGaA is positioned as a leader in several defined niches, including infertility therapeutics, life-science bioprocessing/process solutions, and advanced semiconductor/display materials, with Electronics sharpened into a semiconductor-focused portfolio after the Surface Solutions divestment.
Profitability: The company is described as returning to profitable growth in 2024 and delivering on 2025 guidance, with EBITDA pre improving organically in both years despite foreign exchange headwinds.
Diversified Revenue Streams: The business mix across Life Science, Healthcare, and Electronics is framed as providing resilience, with segment-level growth contributors cited even when certain end markets faced cyclical or project-related softness.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer. We have a legacy of over three decades and trace our origins to the API expertise of Strides Shasun Ltd. and the technical knowhow of human API business from Sequent Scientific Ltd. We are poised to bridge the industry gap by delivering value based products while...
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Financial results indicate steady top-line expansion across recent periods, with growth concentrated in key therapy areas. Double-digit gains in Oncology, Rare Disease, and Respiratory & Immunology help offset headwinds from loss of exclusivity in older products.
Profitability: Earnings are rising and have surpassed external expectations, pointing to solid operating leverage. Core EPS growth alongside revenue expansion signals strengthening bottom-line performance.
Innovation-Driven Growth: A broad late-stage pipeline with multiple positive Phase III readouts and several recent approvals supports long-term growth targets toward 2030. New medicines and blockbuster oncology products are increasingly driving expansion.
Stelis Biopharma is a leading, fully integrated biopharmaceutical contract development and manufacturing organization. The powerhouse to progress your biologic products to market as efficiently as possible, we can cater for the entire product lifecycle for our customers for both drug substances and drug products. Our team has deep expertise in product development and manufacturing with comprehensive capabilities from cell line...
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through...
ArisGlobal is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: AbbVie reported approximately 10.3% year-over-year revenue growth in Q3 2026 to about $17.4 billion and raised its full-year 2026 revenue outlook to roughly $67.8 billion. This acceleration is driven primarily by Skyrizi, Rinvoq, and neuroscience.
Strong Market Position & Advantage: AbbVie holds leading positions in immunology and medical aesthetics, ranking first among 14 immunology companies in a physician survey and benefiting from Allergan Aesthetics brands such as Botox Cosmetic and Juvéderm. These advantages are reinforced by next‑generation therapies Skyrizi and Rinvoq that have helped replace Humira revenue.
Product Line Growth: AbbVie’s growth products are expanding rapidly, with Skyrizi and Rinvoq up roughly 23% and 24% and neuroscience up nearly 20% in the latest quarter. Management expects Skyrizi and Rinvoq to exceed $32 billion in combined 2026 sales, underscoring continued expansion of its immunology portfolio.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the...
CAD Pharma Inc. is a young company incorporated in February 2003. The main objective of the company is to assist customers and associates in sourcing products mainly Active Pharmaceutical Ingredients, Finished Formulations, Excipients And Intermediates. CAD Pharma derives its strength from the rich experience of its promoters and its professional set-up in Bangalore. CAD Pharma goes beyond just sourcing by providing...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Revenue Growth: GSK reported higher sales in 2025 to £32.7 billion and delivered additional growth in Q3 2026, with momentum concentrated in Specialty Medicines, HIV, oncology, and vaccines. The company reaffirmed its 2026 growth guidance and is targeting annual sales of more than £40 billion by 2031.
Profitability: GSK delivered increases in core operating profit in 2025 and again in Q3 2026, showing earnings rising alongside revenue. The 2026 outlook also calls for further growth in core operating profit and EPS, reinforcing a constructive profit trajectory.
Strong Market Position & Advantage: GSK holds leadership positions in vaccines, HIV, respiratory medicine, and infectious diseases, supported by a broad vaccine portfolio and leading respiratory brands such as Trelegy. External benchmarks, including a top-two ranking in the Access to Medicine Index and an industry-leading antimicrobial pipeline, underscore competitive strength in its focus areas.



























.png)






